Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,782
  • Shares Outstanding, K 92,295
  • Annual Sales, $ 0 K
  • Annual Income, $ -65,350 K
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32
Trade APTO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings -0.11 on 11/01/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 297.30% ( -271.49%)
  • Historical Volatility 108.27%
  • IV Percentile 73%
  • IV Rank 27.60%
  • IV High 963.08% on 07/05/22
  • IV Low 43.55% on 02/17/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 3,102

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +59.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4508 +55.70%
on 10/31/22
0.7900 -11.15%
on 11/08/22
+0.2249 (+47.15%)
since 10/25/22
3-Month
0.4508 +55.70%
on 10/31/22
0.8100 -13.35%
on 08/26/22
-0.0904 (-11.41%)
since 08/25/22
52-Week
0.4508 +55.70%
on 10/31/22
2.4000 -70.75%
on 11/26/21
-1.6981 (-70.75%)
since 11/24/21

Most Recent Stories

More News
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

BPMC : 44.89 (+0.13%)
APTO : 0.7019 (+4.78%)
DCPH : 15.93 (+3.37%)
ORIC : 3.50 (-3.58%)
Horizon (HZNP) Completes Enrollment in Phase IV TED Study

Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.

HZNP : 78.28 (+0.97%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

REGN : 736.23 (+0.12%)
SNY : 45.39 (+0.78%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
Merck's (MRK) Keytruda Gets Four New Approvals in Japan

The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.

MRK : 107.50 (+0.64%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

RHHBY : 41.0600 (+1.08%)
SGEN : 123.44 (-0.42%)
APTO : 0.7019 (+4.78%)
LVTX : 5.75 (-0.52%)
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral

Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

EBS : 11.90 (+0.59%)
CMRX : 2.20 (-1.79%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

MRK : 107.50 (+0.64%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
EVAX : 2.10 (-1.18%)
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod

The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

ALNY : 212.72 (+2.03%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion

The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.

PCRX : 49.69 (+1.49%)
ATRA : 4.18 (+0.24%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

RHHBY : 41.0600 (+1.08%)
SGEN : 123.44 (-0.42%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

3rd Resistance Point 0.7363
2nd Resistance Point 0.7206
1st Resistance Point 0.7113
Last Price 0.7019
1st Support Level 0.6863
2nd Support Level 0.6706
3rd Support Level 0.6613

See More

52-Week High 2.4000
Fibonacci 61.8% 1.6554
Fibonacci 50% 1.4254
Fibonacci 38.2% 1.1954
Last Price 0.7019
52-Week Low 0.4508

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar